Skip to main content

Margo Georgiadis

Co-Founder & CEO, Montai Therapeutics; CEO-Partner

Margo Georgiadis is Co-Founder and CEO of Montai Therapeutics, a company pioneering at the intersection of technology, validated biology, and diverse, untapped human chemistry in pursuit of transformative medicines for chronic disease. Montai’s CONECTA platform enables the predictable discovery of efficacious small molecules that can precisely engage complex biologic targets and pathways and have the potential to become medicines for long-term use and earlier intervention. Margo is also a CEO-Partner at Flagship Pioneering, the bioplatform innovation company behind more than 100 scientific ventures in human health and sustainability.  


Margo has dedicated her career to transforming products and services with data and technology to empower consumers to live better lives, and to deliver outsized growth and returns for investors. Prior to founding Montai, she held multiple senior leadership roles including President and CEO of Ancestry and President of Americas and Vice President of Global Operations at Google. She also is an experienced investor and worked at both General Catalyst and Synetro Group building next generation technology and healthcare platforms.  


Margo has received multiple awards for her business and community leadership including being named to Fortune’s “50 Most Powerful Women in Business” and Crain’s “Most Powerful Women in Business lists and recognized with the Forbes “Excellence Award in Innovation,” Chicago Innovation’s “Visionary Award,” the Eastman Medal from the University of Rochester, Women Business Collaborative’s “Trailblazer in Gender Equity and Diversity,” and Executive of the Year in Utah. Margo serves on the Boards of several market leaders and innovators including McDonald’s, Applovin, Handshake, Ro, Harbinger Health and the Parker Institute for Cancer Immunotherapy.